Stockscreener 앱 받기
0.5122
10.70%
-0.0478
전일 마감가:
$0.56
열려 있는:
$0.5471
하루 거래량:
845.09K
Relative Volume:
1.05
시가총액:
$12.44M
수익:
$411.00K
순이익/손실:
$-4.85M
주가수익비율:
-1.1641
EPS:
-0.44
순현금흐름:
$-4.88M
1주 성능:
-14.16%
1개월 성능:
-55.35%
6개월 성능:
-41.82%
1년 성능:
-78.90%
1일 변동 폭
$0.46
$0.5471
1주일 범위
$0.46
$0.6998
52주 변동 폭
$0.46
$2.43
Lexaria Bioscience Corp Stock (LEXX) Company Profile
명칭
Lexaria Bioscience Corp
전화
250-765-6424
주소
100 - 740 MCCURDY ROAD, KELOWNA
LEXX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
0.50 | 13.94M | 411.00K | -4.85M | -4.88M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.90 | 117.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
778.84 | 82.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.95 | 52.94B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.28 | 52.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
178.42 | 37.84B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lexaria Bioscience Corp 주식(LEXX)의 최신 뉴스
Lexaria Bioscience stock price target cut to $1.50 from $4 at H.C. Wainwright - Investing.com
LEXX: HC Wainwright & Co. Lowers Price Target to $1.50, Maintains Buy Rating | LEXX Stock News - GuruFocus
LEXX: DehydraTECH Formulation Reduces GLP-1 Agonist Side Effects - Research Tree
Lexaria’s DehydraTECH-semaglutide cuts GLP-1 side effects in phase 1b trial and extends cash runway into 2026 - MSN
Primary Endpoint Successfully Achieved in Lexaria’s Phase 1b Study GLP-1-H24-4 - Hillsdale Daily News
Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus - Benzinga
Lexaria’s DehydraTECH-Semaglutide Cuts GLP-1 Side Effects in Phase 1b Trial and Extends Cash Runway Into 2026 - TipRanks
Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4 - Investing News Network
Is Lexaria Bioscience Corp. stock resilient to inflationJuly 2025 Market Mood & Weekly Consistent Profit Watchlists - Улправда
What momentum indicators show for Lexaria Bioscience Corp. stockPortfolio Growth Summary & AI Powered Market Trend Analysis - Улправда
Will Lexaria Bioscience Corp. stock deliver better than expected guidanceQuarterly Profit Review & Safe Capital Investment Plans - Улправда
Is Lexaria Bioscience Corp. stock a buy on dipsJuly 2025 Technicals & AI Optimized Trading Strategy Guides - Улправда
Lexaria Bioscience secures $3.5 million in direct offering to boost R&D - MSN
Portfolio Recap: What valuation multiples suggest for Lexaria Bioscience Corp. Equity Warrant stockBreakout Watch & Fast Entry and Exit Trade Plans - Улправда
Setup Watch: Is Lexaria Bioscience Corp. stock resilient to inflationSell Signal & Consistent Profit Trade Alerts - Улправда
How geopolitical tensions affect Lexaria Bioscience Corp. stockJuly 2025 Short Interest & Free Expert Verified Stock Movement Alerts - DonanımHaber
Will Lexaria Bioscience Corp. Equity Warrant stock benefit from AI adoptionWeekly Profit Summary & Risk Managed Trade Strategies - DonanımHaber
Published on: 2025-12-19 15:15:39 - DonanımHaber
Published on: 2025-12-19 14:32:21 - DonanımHaber
Is Lexaria Bioscience Corp. Equity Warrant stock trading at a premium valuationWeekly Earnings Recap & Weekly Top Stock Performers List - Улправда
Momentum Shift: Is Lexaria Bioscience Corp. Equity Warrant stock trading at a premium valuationJuly 2025 Breakouts & Daily Risk Controlled Trade Plans - Улправда
Lexaria Bioscience Corp. (LEXX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Lexaria Bioscience Secures $3.5 Million in Capital Through Registered Direct Offering - citybuzz -
Lexaria Bioscience closes $3.5 million registered direct offering - Investing.com
Lexaria Bioscience (NASDAQ: LEXX) details approximately $3.5 million financing terms - Stock Titan
Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Bluefield Daily Telegraph
Drug delivery company Lexaria raises $3.5M for R&D and working capital - Stock Titan
Lexaria Bioscience Corp. (NASDAQ: LEXX) offers 2,661,600 new shares of common stock - Stock Titan
Lexaria Bioscience plummets on $3.5M equity offering - MSN
Lexaria Bioscience raises $3.5 million in at-market offering By Investing.com - Investing.com Nigeria
Lexaria Bioscience raises $3.5 million in at-market offering - Investing.com India
Lexaria Bioscience Secures $3.5 Million in Direct Offering to Boost R&D - TipRanks
Lexaria Bioscience Corp. (LEXX) Drops 28% in Pre-market: Following Direct Offering Announcement - Stocks Telegraph
LEXX Appoints H.C. Wainwright & Co. as Exclusive Placement Agent - GuruFocus
Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Investing News Network
Lexaria Bioscience stock plunges after $3.5M at-the-market offering - Investing.com Canada
Lexaria (NASDAQ: LEXX) prices $3.5M direct stock offering, adds 5-year warrants - Stock Titan
Lexaria Bioscience (NASDAQ:LEXX) Downgraded by Wall Street Zen to “Sell” - Defense World
Lexaria Bioscience (Nasdaq: LEXX) updates prospectus for 314,287 warrant shares - Stock Titan
How Lexaria Bioscience Corp. Equity Warrant stock performs in high volatility markets2025 Support & Resistance & Intraday High Probability Setup Alerts - Newser
How Lexaria Bioscience Corp. Equity Warrant stock compares to growth peersJuly 2025 Setups & Verified Technical Signals - Newser
Is Lexaria Bioscience Corp. stock a safe haven assetTake Profit & Risk Adjusted Buy and Sell Alerts - Newser
Lexaria Bioscience (LEXX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Lexaria Bioscience Corp. (NASDAQ:LEXX): Are Analysts Optimistic? - Yahoo Finance
Lexaria Bioscience (NASDAQ:LEXX) Stock Rating Upgraded by Wall Street Zen - Defense World
Lexaria Bioscience Corp. SEC 10-K Report - TradingView
Lexaria Bioscience : Annual Report for Fiscal Year Ending 08-31, 2025 (Form 10-K) - marketscreener.com
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended - Investing News Network
Lexaria Bioscience Corp. Reports Earnings Results for the Full Year Ended August 31, 2025 - marketscreener.com
Lexaria Bioscience Corp Stock Analysis and ForecastVolatility Index Analysis & Unlock Long-Term Capital Growth Ideas - earlytimes.in
Lexaria Bioscience Corp (LEXX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.28%
0.67%
자본화:
|
볼륨(24시간):